WO2015026939A1 - Inducteurs chimiques d'hémoglobine foetale - Google Patents

Inducteurs chimiques d'hémoglobine foetale Download PDF

Info

Publication number
WO2015026939A1
WO2015026939A1 PCT/US2014/051887 US2014051887W WO2015026939A1 WO 2015026939 A1 WO2015026939 A1 WO 2015026939A1 US 2014051887 W US2014051887 W US 2014051887W WO 2015026939 A1 WO2015026939 A1 WO 2015026939A1
Authority
WO
WIPO (PCT)
Prior art keywords
thalassemia
beta
agent
hbf
blood
Prior art date
Application number
PCT/US2014/051887
Other languages
English (en)
Inventor
Susan P. Perrine
Douglas V. Faller
Original Assignee
Phoenicia Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phoenicia Biosciences, Inc. filed Critical Phoenicia Biosciences, Inc.
Priority to CA2922013A priority Critical patent/CA2922013C/fr
Publication of WO2015026939A1 publication Critical patent/WO2015026939A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • the present invention is directed to methods and compositions for the treatment of the beta-globin blood disorders sickle cell disease and beta-thalassemia and, in particular, compositions and methods comprising ambroxol, benserazide, desloratadine, resveratrol, NSC- 95397, and/or MS-275 (entinostat).
  • Inherited disorders of production of the beta-chain of adult hemoglobin A (beta- thalassemia) or mutations affecting the structure of the beta-globin chain (sickle cell disease) are the most common genetic diseases in the world, afflicting millions of individuals worldwide, and are designated by WHO as a global health burden.
  • Disorders of hemoglobin synthesis include deficiencies of globin synthesis such as thalassemia syndromes and structural abnormalities of globin such as sickle cell syndromes and syndromes associated with unstable hemoglobins.
  • beta hemoglobin disorders are characterized by hemolytic anemia, shortened red blood cell lifespan, which reduces oxygen transport throughout the body and multi-organ damage.
  • Pharmacological augmentation of fetal hemoglobin (beta-globin chain) production, to replace the defective or missing beta-globin chains, is a promising therapeutic approach.
  • Fetal globin (also known as gamma globin) normally combines with alpha globin chains prenatally to form fetal hemoglobin (HbF). Fetal globin is replaced by beta globin after birth, which then combines with alpha globin to form adult hemoglobin A. Fetal globin performs the same function as beta globin, and can combine with the alpha chains to generate a healthy form of hemoglobin thereby reducing high concentrations of unmatched alpha globin chains.
  • the various types of beta-thalassemias are syndromes resulting from mutations which produce a deficiency of globin chains.
  • RBCs red blood cells
  • RBC progenitors the unmatched alpha globin chains aggregate inside red blood cells (RBCs) and their progenitors, causing the premature destruction of RBCs and RBC progenitors, which results in anemia, transfusion-dependence, iron overload, organ failure, and early death.
  • SCD sickle cell disease
  • HbS sickling hemoglobin
  • Polymerization results in "sickling" of RBCs.
  • the sickled RBCs undergo hemolysis, while adhesive sickled RBCs occlude the microcirculation, provoking widespread tissue ischemia and organ infarction.
  • the natural history of SCD is marked by painful crises and acute chest syndrome, and eventual potentially life-threatening sequelae, including renal insufficiency, retinitis, osteonecrosis, osteomyelitis, aplastic crises, functional asplenism, stroke, priapism, and severe pulmonary hypertension.
  • HbF human immunoglobulin Diffraction
  • F-cells red blood cells expressing HbF
  • HU HbF stimulant therapeutic
  • HU hydroxyurea
  • HbF levels achieved are often not sufficiently high to completely ameliorate all complications. Additional therapeutics, especially non-cytotoxic agents which can be used in combinations with HU, could provide additional benefit.
  • Fetal hemoglobin (HbF, gamma2alpha2) produced by the gamma-globin gene (HBG), is the major human hemoglobin in utero, and is replaced by beta-globin expression in infancy, even when the beta-globin genes are mutated. Fetal globin when present in even small amounts prevents sickling. In beta-thalassemia, increasing synthesis of fetal globin chains reduces the globin chain imbalance, caused by excess of alpha globin and deficiency of beta globin, and consequent anemia. Fetal globin is the major modulator of disease severity and a generally- accepted target for drugs to ameliorate these diseases.
  • HbF inducers A major unmet medical need exists for high-potency HbF inducers, particularly for patients with lower baseline levels of HbF, and for the many who do not have a robust response to HU alone.
  • a combination chemotherapy approach is needed to increase response rates in sickle disease.
  • Baseline HbF expression is influenced by genetic modifiers.
  • the 3 most influential quantitative trait loci (QTLs) are responsible for 50% of variability in HbF levels. Polymorphisms in these QTLs are associated with higher baseline HbF levels.
  • QTL, BCL-11A is a repressor of fetal globin synthesis.
  • the inventions have been identified to suppress the expression of this repressor at the mRNA and protein levels.
  • Several of these drug candidates act, in part, through suppression of repressors of fetal globin (Bcl-11 A, LSD-1, HDAC-3, HDAC-2, and KLF-1).
  • the thalassemia syndromes are a heterogeneous group of disorders all characterized by a lack of or a decreased synthesis of the globin chains of HbA. Deficiencies of alpha-globin expression are referred to as alpha-thalassemias and deficiencies of beta-globin, beta- thalassemias.
  • the hemolytic consequences of deficient globin chain synthesis result from decreased synthesis of one chain and also an excess of the complementary chain. Free chains tend to aggregate into insoluble inclusions within erythrocytes causing premature destruction of maturing erythrocytes and their precursors, ineffective erythropoiesis, and the hemolysis of mature red blood cells.
  • the underlying defects of hemoglobin synthesis have been elucidated over the years and largely reside in the nucleic acid sequences which express or control the expression of alpha or beta-globin protein.
  • HbF human neoplasm originating from sickle cell disease and beta-thalassemia.
  • cytotoxic chemotherapeutic agents such as cytotoxic chemotherapeutic agents
  • HU Hydroxyurea
  • EPO erythropoietin
  • SCFAs short chain fatty acids
  • SCFADs short chain fatty acids
  • H 2 NCONHOH another relatively small molecule, was found to stimulate globin expression (N.L. Letvin et al., N. Engl. J. Med. 310:869-73, 1984). Stimulation, however, did not appear to be very specific to fetal globin (S. Charache et al., Blood 69: 109-16, 1987). Hydroxyurea (HU) is also a well-known carcinogen making its widespread and long term use as a pharmaceutical impractical.
  • SCFA agents While three SCFA agents have been reported to induce gamma-globin expression and to increase hemoglobin levels in subjects with beta-thalassemia, rendering some beta- thalassemia subjects transfusion- independent, these prior generations of SCFAs, including arginine butyrate (AB) and sodium phenylbutyrate (SPB), have limited utility as a therapeutic agent in vivo, as they are either rapidly metabolized, required intravenous (IV) infusions, or required large doses which were difficult for subjects to tolerate long-term. Furthermore, these first generation SCFAs are also known to inhibit erythroid cell proliferation, and therefore require titration and intermittent dosing, complicating their use in conditions of anemia where compensatory erythroid cell proliferation is desirable. There, thus remains an unmet clinical need for a therapeutic agent that induces gamma-globin gene expression and does not inhibit erythroid cell proliferation (i.e., is not cytotoxic), and which is more applicable for wide application in these genetic diseases.
  • AB
  • the present invention relates to agents that function as fetal globin-inducing agents, for the treatment of beta-globin disorders, such as sickle cell anemia and beta-thalassemias, with higher efficacy than prior generation agents in predictive in vivo models and which do not have the limitations of prior generation candidates for long term use.
  • Lead candidates were investigated in in vivo non-primate models. While some identified compounds are already FDA-approved for other medical indications, their safety profiles are benign and they are not known to increase fetal-globin expression. Accordingly, subjects in need of increased fetal-globin expression can be selected and administered the compounds identified herein for treatment of beta-globin diseases, such as Sickle Cell Disease and the diverse variations of beta-thalassemia syndromes.
  • beta-globin diseases such as Sickle Cell Disease and the diverse variations of beta-thalassemia syndromes.
  • Fetal hemoglobin (HbF: alpha2, gamma2) is an endogenous type of hemoglobin which is present in all humans, but is normally suppressed in infancy to levels below 2%.
  • HbF and F-cell levels reduce the severity of sickle cell disease, or alleviate the anemia of beta- thalassemia. It is well-established that fetal globin (gamma-globin) chains interfere with the polymerization of sickle hemoglobin, preventing many pathologic consequences of sickling, and also that adequate levels of fetal hemoglobin (also referred to as hemoglobin F or HbF), correlate with mild or benign courses in sickle cell disease (SCD).
  • SCD sickle cell disease
  • HbF fetal hemoglobin
  • gamma-globin fetal hemoglobin
  • the present invention generally relates to increasing the percentage of fetal hemoglobin (HbF or gamma-globin) in the blood of a subject without decreasing proliferation of cells, the method comprising administering to the subject a composition comprising at least one of, or any combination of HbF-inducing drugs, which include, ambroxol, benserazide, desloratadine, resveratrol, NSC-95397, or MS-275.
  • HbF-inducing drugs include, ambroxol, benserazide, desloratadine, resveratrol, NSC-95397, or MS-275.
  • the composition comprises benserazide or desloratadine or MS- 275, or any pharmaceutically acceptable salt, polymorph or ester thereof.
  • compositions that comprise one or more compounds which stimulate the proliferation of hemoglobin-producing cells, the expression of hemoglobin or the expression of embryonic or fetal globin in mammalian cells.
  • Chemical compounds, or HbF-inducing agents include, ambroxol, benserazide, desloratadine, resveratrol, NSC-95397, or MS-275.
  • compositions comprising at least one or any combination of HbF-inducing agents selected from the group of ambroxol, benserazide, desloratadine, resveratrol, NSC-95397, or MS-275, in particular benserazide, desloratadine or MS-275 that stimulate the proliferation of hemoglobin producing and other types of cells, the expression of hemoglobin or the expression of embryonic or fetal globin in mammalian cells, but do not decrease or otherwise adversely affect cell viability.
  • HbF-inducing agents include benserazide, desloratadine or MS-275.
  • Cell viability may be assayed by DNA fragmentation assays or cell division assays, or by measuring the amount of nucleic acid or protein synthesis which occurred in treated cells as compared to untreated cells.
  • Cells tested may be normal healthy cells, subject cells to be treated or cells in tissue culture.
  • HbF-inducing agents selected from the group including, ambroxol, benserazide, desloratadine, resveratrol, NSC-95397, or MS-275, in particular benserazide, desloratadine or MS-275 which stimulate the proliferation of hemoglobin producing cells or the expression of embryonic or fetal globin from cells are administered to patients.
  • Patients may be any mammal such as a human.
  • Administration may be by parenteral or nonparenteral means, but is preferably oral or intravenous.
  • Treatment may be for short periods of time, e.g., pulsed or continuous throughout the lifetime of the patient.
  • Another embodiment of the invention is directed to methods for the treatment of blood disorders comprising the administration of compositions containing therapeutically effective amounts of an HbF-inducing agent selected from at least one or any combination of ambroxol, benserazide, desloratadine, resveratrol, NSC-95397, or MS-275, in particular benserazide, desloratadine or MS-275 which increases the proportion or number of reticulocytes that express embryonic or fetal globin and the amount of embryonic or fetal globin expressed per cell.
  • an HbF-inducing agent selected from at least one or any combination of ambroxol, benserazide, desloratadine, resveratrol, NSC-95397, or MS-275, in particular benserazide, desloratadine or MS-275 which increases the proportion or number of reticulocytes that express embryonic or fetal globin and the amount of embryonic or fetal
  • Another embodiment of the invention is directed to methods for regulating the expression of a globin gene such as an embryonic or fetal globin gene or an at least partially functional pseudo-globin gene in mammalian cells.
  • treated cells e.g., ex vivo, or products expressed from these cells, can be harvested and introduced or reintroduced to a subject to treat or prevent a blood disorder.
  • Another embodiment of the invention is directed to methods for regulating the proliferation of hemoglobin expressing cells.
  • Cells in culture or in patients are exposed to compositions of HbF-inducing agents selected from the group including, at least one or any combination of ambroxol, benserazide, desloratadine, resveratrol, NSC-95397, or MS-275, in particular benserazide, desloratadine or MS-275 and induced to proliferate.
  • HbF-inducing agents selected from the group including, at least one or any combination of ambroxol, benserazide, desloratadine, resveratrol, NSC-95397, or MS-275, in particular benserazide, desloratadine or MS-275 and induced to proliferate.
  • the subject may be any mammal such as a human and is preferably an adolescent, child, or infant.
  • Administration may be by any route including parenteral and nonparenteral routes, but is preferably oral or intravenous. Treatment may be for short periods of time or continuous throughout the lifetime of the patient.
  • FIG. 1A is a schematic showing an illustration of the high throughput screening assay (HTS) with the cell construct comprising a locus control region (LCR) linked to the gamma-globin gene promoter and enhanced GFP (EGFP).
  • HTS high throughput screening assay
  • Figure IB depicts a small panel of approved therapeutics were found to induce ⁇ -globin expression from the library of compounds and US and EMA approved medicinal products tested.
  • Figure 2 shows a table of the fold increase fetal globin mRNA in erythroid progenitors in response to benserazide and MS-275 and other compounds identified in the high-throughput screen.
  • Figure 3 shows gamma-globin mRNA expression in the blood of baboons administered fetal hemoglobin inducing agent benserazide.
  • Benserazide was compared to 2 other candidates (i) desloratadine (DLT), which was administered orally (0.5 mg/kg/dose), three times a week over two weeks, and (ii) MS-275, which was administered orally three times a week for two weeks at 0.2 mg/kg/dose. Doses of Benserazide are shown in the bars above the graph, with Benserazide administered at 1 mg/kg (Open squares) and 2 mg/kg (dark squares). Benserazide resulted in up to 33-fold induction of gamma-globin mRNA in vivo (Figure 3A) and an increase in total hemoglobin (Hb) (by 1.5g/dL)
  • Figure 4 shows the mean induction of fetal globin with Benserazide (BEN) and Desloratidine (DLT) as compared to other inducers in the Anaemic Baboon model.
  • Benserazide induced fetal globin mRNA by a mean of 27-fold; Desloratidine (DLT) induced a 11-fold increase above baseline.
  • Figure 5 shows the mean increase of induction of F-Reticulocytes during and after
  • Benserazide BEN
  • Figure 6 shows the effect of benserazide compared to a known Hb inducer (Hydoxyurea (HU) in a transgenic mice model comprising the entire human non-alpha (gamma delta beta-globin) gene locus.
  • Benserazide induced a mean increase in total hemoglobin (Hb) at 5 weeks (Figure 6A) and induced an absolute 13% mean increase in the number of F-cells (from 0.1% to 9% (mice #1), 0.4% to 18% (mice #2), and 0.13% to 12% (mice #3); and 10 to 33-fold increase in mean fluorescence intensity (MFI) (Figure 6B).
  • Figure 9 depicts a comparison of the magnitude of fetal globin mRNA induction over baseline levels in anemic baboons by new drugs compared to hydroxyurea (HU) ( Figure 9A), and proportions of new red blood cells with fetal globin protein, F-reticulocytes, (Figure 9B).
  • Figures 10A-F depict Benserazide reduction of binding of two repressors, LSDl and HDAC3, to the fetal globin gene promoter in erythroid progenitors from sources as indicated.
  • Figure 11 depicts the suppression of repressor proteins BCLl 1A and KLFl in different erythroid progenitors treated with new drugs as compared with untreated control levels by Western blot analysis.
  • the present invention is directed to compounds, compositions and methods that increase gamma-globin expression in vivo, and in particular, compounds, compositions and methods for the treatment of gamma-globin disorders such as, but not limited to Sickle Cell anemia and beta- thalassemia.
  • the present invention generally relates to increasing the percentage of fetal hemoglobin (HbF or gamma-globin) in the blood of a subject, the method comprising administering to the subject a composition comprising at least one of, or any combination of ambroxol, benserazide, desloratadine, resveratrol, NSC-95397, or MS-275.
  • HbF fetal hemoglobin
  • the composition comprises benserazide or desloratadine or MS-275, or any pharmaceutically acceptable salt, polymorph or ester thereof.
  • pharmaceutically acceptable excipient refers to carriers and vehicles that are compatible with the active ingredient (for example, a compound of the invention) of a pharmaceutical composition of the invention (and preferably capable of stabilizing it) and not deleterious to the subject to be treated.
  • solubilizing agents that form specific, more soluble complexes with the compounds of the invention can be utilized as pharmaceutical excipients for delivery of the compounds.
  • Suitable carriers and vehicles are known to those of extraordinary skill in the art.
  • excipient as used herein will encompass all such carriers, adjuvants, diluents, solvents, or other inactive additives.
  • Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid esters, hydroxymethyl-cellulose, polyvinylpyrrolidone, etc.
  • compositions of the invention can also be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like, which do not deleteriously react with the active compounds of the invention.
  • auxiliary agents e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like, which do not deleteriously react with the active compounds of the invention.
  • the term "pharmaceutically acceptable salt,” is a salt formed from an acid and a basic group of a compound of the invention.
  • Illustrative salts include, but are not limited, to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutarnate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate salts.
  • Suitable bases include, but are not limited to, hydroxides of alkali metals such as sodium, potassium, and lithium; hydroxides of alkaline earth metal such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; ammonia, and organic amines, such as unsubstituted or hydroxy-substituted mono-, di-, or trialkylamines; dicyclohexylamine; tributyl amine; pyridine; N-methyl, N-ethylamine; diethylamine; triethylamine; mono-, his-, or tris-(2-hydroxy-lower alkyl amines), such as mono-, his-, or tris-(2-hydroxyethyl)amine, 2-hydroxy-tert-butylamine
  • a prodrug refers to compounds that can be converted via some chemical or physiological process (e.g., enzymatic processes and metabolic hydrolysis).
  • the prodrug compound often offers advantages of solubility, or delayed release in an organism.
  • the term “prodrug” is also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a subject.
  • Prodrugs of an active compound may be prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent active compound.
  • Prodrugs include compounds wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively.
  • prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of an alcohol or acetamide, formamide and benzamide derivatives of an amine functional group in the active compound and the like.
  • subject is used interchangeably herein with “patient” and refers to a vertebrate, preferably a mammal, more preferably a primate, still more preferably a human.
  • Mammals include, without limitation, humans, primates, wild animals, rodents, feral animals, farm animals, sports animals, and pets.
  • Primates include chimpanzees, cynomologous monkeys, spider monkeys, and macaques, e.g., Rhesus.
  • Rodents include mice, rats, woodchucks, ferrets, rabbits and hamsters.
  • Domestic and game animals include cows, horses, pigs, deer, bison, buffalo, feline species, e.g., domestic cat, canine species, e.g., dog, fox, wolf, avian species, e.g., chicken, emu, ostrich, and fish, e.g., trout, catfish and salmon.
  • Patient or subject includes any subset of the foregoing, e.g., all of the above, but excluding one or more groups or species such as humans, primates or rodents.
  • the subject is a mammal, e.g., a primate, e.g., a human.
  • a subject can be male or female.
  • terapéuticaally effective amount refers to an amount sufficient to affect a beneficial or desired clinical result upon treatment.
  • a “therapeutically effective amount” is an amount of a compound of this invention sufficient to confer a therapeutic or prophylactic effect on the treated subject a hemoglobinopathy and/or thalassemia.
  • Therapeutically effective amounts will vary, as recognized by those skilled in the art, depending on the specific disease treated, the route of administration, the excipient selected, and the possibility of combination therapy. Generally, a therapeutically effective amount can vary with the subject's history, age, condition, sex, as well as the severity and type of the medical condition in the subject, and administration of other pharmaceutically active agents.
  • statically significant refers to statistical significance and generally means a two standard deviation (2 SD) below normal, or lower, concentration of the marker.
  • the term refers to statistical evidence that there is a difference. It is defined as the probability of making a decision to reject the null hypothesis when the null hypothesis is actually true. The decision is often made using the p-value.
  • substantially means a proportion of at least about 60%, or preferably at least about 70% or at least about 80%, or at least about 90%, at least about 95%, at least about 97% or at least about 99% or more or any integer between 70% and 100%.
  • compositions, methods, and respective component(s) thereof that are essential to the invention, yet open to the inclusion of unspecified elements, whether essential or not.
  • the term "consisting essentially of” refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment of the invention.
  • compositions, methods, and respective components thereof as described herein, which are exclusive of any element not recited in that description of the embodiment.
  • the present invention generally relates to increasing the percentage of fetal hemoglobin (HbF or gamma-globin) in the blood of a subject, the method comprising
  • compositions comprising at least one of, or any combination of HbF-inducing agents, selected from the group comprising; ambroxol, benserazide, desloratadine, resveratrol, NSC-95397, or MS-275.
  • HbF-inducing agents selected from the group comprising; ambroxol, benserazide, desloratadine, resveratrol, NSC-95397, or MS-275.
  • an HbF-inducing agent is benserazide or desloratadine or MS-275, or any pharmaceutically acceptable salt, polymorph or ester thereof.
  • the amount of fetal globin in the blood of the subject increases with administration of an HbF-inducing agent as disclosed herein to the subject.
  • the number of F-cells in the blood of the subject increases with administration of one or more HbF-inducing agent as disclosed herein.
  • the number of F- reticulocytes in the blood of the subject increases on administration of an HbF-inducing agent as disclosed herein.
  • the amount of total fetal hemoglobin in the blood of the subject increases.
  • the amount of total hemoglobin in the blood of the subject increases.
  • hematocrit increases.
  • red blood cell production increases.
  • a composition comprising at least one HbF-inducing agent as disclosed herein is administered in an effective amount to increase the expression of gamma- globin in the blood by a statistically significant increase as compared to in the absence of a compound. In some embodiments, a composition comprising at least one HbF-inducing agent as disclosed herein is administered to increase the expression of gamma-globin in the blood by a statistically significant increase as compared to in the presence of a control agent
  • a composition comprising at least one HbF-inducing agent as disclosed herein, for example, any one, or any combination of ambroxol, benserazide, desloratadine, resveratrol, NSC-95397, or MS-275, or in particular, benserazide, desloratadine, or MS-275 is administered in an effective amount to increase the level of gamma-goblin expression in blood by at least about 2%, as compared to either in the absence of the composition, or as compared to a positive control agent, such ST20.
  • HbF-inducing agent as disclosed herein, for example, any one, or any combination of ambroxol, benserazide, desloratadine, resveratrol, NSC-95397, or MS-275, or in particular, benserazide, desloratadine, or MS-275 is administered in an effective amount to increase the level of gamma-goblin expression in blood by at
  • a composition comprising at least one HbF-inducing agent as disclosed herein, for example, any one, or any combination of ambroxol, benserazide, desloratadine, resveratrol, NSC-95397, or MS-275, or in particular, benserazide, desloratadine, or MS-275 is administered in an effective amount to increase the total hemoglobin in the blood above the baseline.
  • administration of one or more HbF-inducing agent is a pulsed administration.
  • a pulsed administration comprises administering one or more HbF-inducing agent for about 8 weeks, followed by not administering an HbF-inducing agent for about 4 weeks.
  • the pulsed administration comprises
  • the pulsed administration comprises administering at least one HbF-inducing agent for about 6 weeks, followed by not administering an HbF-inducing agent for about 2 weeks.
  • the pulsed administration comprises administering at least one HbF-inducing agent for about 4 weeks, followed by not administering an HbF-inducing agent for about 2 weeks.
  • the pulsed administration comprises administering at least one HbF-inducing agent for about 4 days a week or for about 2 weeks or 4 weeks, followed by not administering an HbF-inducing agent for about 1 week or 2 weeks.
  • pulsed administration comprises pulses of administering at least one HbF-inducing agent for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 9 months, about 12 months.
  • pulsed administration comprises intervals of not administering an HbF-inducing agent of about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 9 months, about 12 months.
  • an HbF-inducing agent of about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 9 months, about 12 months.
  • administration is continuous. In certain embodiments, administration is for the lifetime of the subject.
  • a subject is a mammal.
  • a mammal is an animal.
  • an animal is a horse or a dog.
  • the mammal is a human.
  • the human is a child.
  • a human is under the age of 18.
  • a human is under the age of 10.
  • a human is under the age of 2.
  • kits for increasing the percentage of fetal hemoglobin in the blood of a subject diagnosed with a beta- thalassemia comprising administering to the subject a composition comprising at least one HbF-inducing agent or a pharmaceutically acceptable salt, or ester thereof, wherein after the administration the percentage of fetal hemoglobin in the blood of the subject increases by a statistically significant amount as compared to the absence of administration of the HbF-inducing agent, or a control agent, such as, for example, ST20.
  • provided herein are methods for increasing the percentage of fetal hemoglobin in the blood of a subject diagnosed with a beta- thalassemia comprising
  • composition comprising one or more HbF-inducing agents, as the free acid, a pharmaceutically acceptable salt, or ester thereof.
  • the percentage of fetal hemoglobin in the blood of a subject increases after one week of administering as compared to baseline. In other embodiments the percentage of fetal hemoglobin in the blood of a subject increases after two weeks of
  • the percentage of fetal hemoglobin in the blood of a subject increases after four weeks of administering as compared to baseline. In some embodiments, the percentage of fetal hemoglobin in the blood of a subject increases after one day of administering as compared to baseline. In certain embodiments the percentage of fetal hemoglobin in the blood of a subject increases after 3 days of administering as compared to baseline.
  • the methods for increasing the percentage of fetal hemoglobin further comprises administering to the subject at least one other therapeutic agent with at least one HbF-inducing agent, wherein the therapeutic agent can be selected from the group consisting of; hydroxyurea, decitabine, an HDAC inhibitor, sodium 2,2 dimethylbutyrate, ST20 or any combination thereof.
  • the therapeutic agent can be selected from the group consisting of; hydroxyurea, decitabine, an HDAC inhibitor, sodium 2,2 dimethylbutyrate, ST20 or any combination thereof.
  • Benserazide (also called SERAZIDETM or Ro 4-4602) is a peripherally- acting aromatic L-amino acid decarboxylase (AAAD) or DOPA decarboxylase inhibitor, which is unable to cross the blood-brain barrier ( Figure 7).
  • Benserazide has a systematic (IUPAC) name (RS)-2-amino- 3-hydroxy-N' -(2,3,4- trihydroxybenzyl)propanehydrazide, and CAS number 14919-77-8 and formula: C10H15N3O5, and Molecular mass of 257.243 g/mol.
  • Desloratadine known as 8-chloro-6,l l-dihydro-l l-(4-piperidylidene)- 5H-benzo[5,6]cyclohepta[l,2-b-]pyridine ( Figure 7).
  • Desloratadine is currently marketed as CLARINEXTM in the United States.
  • CLARINEXTM is prescribed as an antihistamine for prevention or treatment of allergenic reactions, which may result in symptoms such as sneezing, itchy eyes and hives U.S. Pat. No.
  • Descarbonylethoxyloratadine also known as Desloratadine
  • Desloratadine which possesses antihistaminic properties with substantially no sedative properties.
  • the 4,659,716 patent describes a process for the preparation of Desloratadine by dissolving loratadine in water and basifying with dilute solution of potassium carbonate to obtain a pink-colored oil. The organic material is extracted with chloroform, washed with water and triturated with hexane.
  • Desloratadine is obtained by recrystallisation of the extracted organic material with large volume of hexane after charcolisation.
  • Ether solvents such as dioxane produced form 1 substantially free of form 2 but other alkane ethers, e.g., di-isopropyl ether produced form 1 with significant amounts of form 2 and di-n-butyl ether favored formation of form 2.
  • Ketones such as methyl isobutyl ketone produced crystalline polymorph form 1 essentially free of form 2 but methyl butyl ketone produced 8: 1 ratio of form 1 to form 2.
  • Use of methyl isobutyl ketone is preferred to produce crystalline polymorph form 1 essentially free of form 2. Only ethyl acetate and di-n-butyl ether were found to produce crystalline polymorph form 2 substantially free of form 1.
  • Use of di-n- butyl ether is preferred for producing crystalline form 2 substantially free of form 1.
  • the polymorph form obtained from U.S. Pat. No. 4,659,716 is a mixture of form I and form II.
  • Desloratadine or its pharmaceutically acceptable salts thereof can be used in the methods and compositions as disclosed herein, and are well known in the art and is disclosed and can be manufactured as taught in the following U.S. Patent Applications, 2010/0129310; 2010/0216831; 2010/0069402; 2010/0022576; 2010/0021542; 2008/0118555; 2007/0244144; 2007/0135472; 2007/0060756; 2007/0053974; 2007/0014855; 2007/0004671; 2006/0276495; 2006/0223841; 2006/0154948; 2006/0100435, which are incorporated herein in their entirety by reference.
  • MS-275 is also called MS-27-275 or N-(2-arninophenyl)-4-[N-(pyridin-3- yl-methoxycarbonyl)arninomethyl]benzarnide ( Figure 7).
  • MS-275 is also commonly known in the art as Entinostat, and is an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor with a long half-life that allows for weekly or every- other-week dosing.
  • HDAC histone deacetylase
  • Entinostat is currently being investigated in multiple phase 2 clinical studies in cancer in combination with other agents.
  • MS-275 is a synthetic benzamide derivative that has been shown to inhibit cellular histone deacetylase activity and to block growth in a variety of human tumor cell lines (A. Saito, et al., 1999, Proc. Natl. Acad. Sci. USA, A synthetic inhibitor of histone deacetylase, MS-27- 275, with marked in vivo antitumor activity against human tumors, 96:4592-7).
  • the chemical structure of MS-275 (structure I in Figure 8).
  • MS-275 is chemically synthesized using methods known in the art. One such method is described in T. Suzuki et al., 1999, J. Med. Chem., Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives, 42:3001-3.
  • MS-275 is also available from various sources.
  • One such source is Nihon Schering K.K.
  • Another source is the National Cancer Institute (MS-275 is NSC No. 706995).
  • MS-275 is NSC No. 706995.
  • Two benzamide derivatives closely related to MS-275 (structures II and III in Figure 8).
  • MS-275 can have derivatives as shown as structures I, II and III, in U.S. Patent 6,841,565, which is incorporated herein in its entirety by reference.
  • MS-275 A polymorph of MS-275 is disclosed in GB patent GB0907347.9 entitled N-(2-aminophenyl)-4- [N-(pyridine-3-YL)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B, which is incorporated herein in its entirety by reference.
  • the invention relates to compositions for the treatment and prevention of blood disorders such as anemia, thalassemia, and sickle cell disease.
  • Compositions stimulate the specific expression of a gamma-globin protein, without inhibiting cell proliferation, and can increase the development of hemoglobin-expressing or other myeloid cells.
  • the invention relates to methods and medical aids which utilize these compositions to treat blood disorders and/or to ameliorate symptoms associated with blood disorders.
  • blood disorders as used herein includes hemoglobinopathies and thalassemias. Blood disorders include disorders that can be treated, prevented, or otherwise ameliorated by the administration of a compound of the invention. Treatable blood disorders also include syndromes such as hemoglobin C, D and E disease, hemoglobin lepore disease, and HbH and HbS diseases. Treatment ameliorates one or more symptoms associated with the disorder.
  • Compositions provided to the subject may include any combination of the proteins or chemical compounds of the invention or known to those of ordinary skill in the art.
  • Administration of the composition may be short term, continuous or sporadic as necessary.
  • Patients with a suspected or diagnosed with a blood disorder may only require composition treatment for short periods of time or until symptoms have abated or have been effectively eliminated.
  • compositions to be administered contain a therapeutically effective amount of a chemical compound.
  • a therapeutically effective amount is that amount which has a beneficial effect to the subject by alleviating one or more symptoms of the disorder or by simply reducing premature mortality.
  • a beneficial effect may be a decrease in pain on an annual or daily basis, a decrease in duration, frequency or intensity of pain crises, an increased hematocrit, an improved erythropoiesis with decreased hemolysis, decrease in fatigue or an increased endurance or stamina or walking ability to walk a certain distance without shortness of breath, or increased strength.
  • a therapeutic amount is that amount of chemical compound or agent that stimulates or enhances the expression of non-adult globin such as embryonic or fetal globin (HbF), or the proliferation of embryonic, fetal globin expressing cells.
  • a therapeutic amount is that amount of chemical compound or agent as disclosed herein that increases the percentage of expression of non-adult globin such as embryonic or fetal globin (HbF), or the proliferation of embryonic, fetal or adult globin expressing cells.
  • compositions comprising at least one or any combination of ambroxol, benserazide, desloratadine, resveratrol, NSC-95397, or MS-275, in particular benserazide, desloratadine or MS-275 can be directly or indirectly administered to the patient.
  • Indirect administration can also be performed, for example, by administering the composition to cells ex vivo and subsequently introducing the treated cells to the patient.
  • the cells may be obtained from the subject to be treated or from a genetically related or unrelated patient.
  • Related patients offer some advantage by lowering the immunogenic response to the cells to be introduced. For example, using techniques of antigen matching, immunologically compatible donors can be identified and utilized.
  • Direct administration of compositions comprising at least one or any combination of ambroxol, benserazide, desloratadine, resveratrol, NSC-95397, or MS-275, in particular benserazide, desloratadine or MS-275 can also be by oral, parenteral, sublingual, rectal such as suppository or enteral administration, or by pulmonary absorption or topical application.
  • Parenteral administration may be by intravenous injection, subcutaneous injection.
  • a composition comprising at least one or any combination of ambroxol, benserazide, desloratadine, resveratrol, NSC-95397, or MS-275, in particular benserazide, desloratadine or MS-275 can be administered by transdermal transfusion such as with a dermal or cutaneous patch, by direct contact with, for example, bone marrow through an incision or some other artificial opening into the body.
  • Compositions may also be administered to the nasal passages as a spray. Arteries of the nasal area provide a rapid and efficient access to the bloodstream and immediate access to the pulmonary system.
  • compositions may be administered as a bolus injection or spray, or administered sequentially over time (episodically) such as every two, four, six or eight hours, every day (QD) or every other day (QOD), or over longer periods of time such as weeks to months.
  • Compositions may also be administered in a timed-release fashion such as by using slow-release resins and other timed or delayed release materials and devices.
  • Orally active compositions comprising at least one or any combination of ambroxol, benserazide, desloratadine, resveratrol, NSC-95397, idarubicin or MS-275, in particular benserazide, desloratadine or MS-275 are more preferred as oral administration is usually the safest, most convenient and economical mode of drug delivery. Oral administration is usually disadvantageous because compositions are poorly absorbed through the gastrointestinal lining. Compounds which are poorly absorbed tend to be highly polar. Consequently, compounds which are effective, as described herein, may be made orally bioavailable by reducing or eliminating their polarity. This can often be accomplished by formulating a composition with a
  • Prophylactic treatments involve administration of a composition of the invention to a subject having a confirmed or suspected blood disorder without having any overt symptoms.
  • a composition of the invention may be administered compositions of the invention prophylactically. Administration can begin at birth and continue, if necessary, for life. Both prophylactic and therapeutic uses are readily acceptable because these compounds are generally safe and non-toxic.
  • Individual pulses of an HbF-inducing agent as disclosed herein can be delivered to the patient continuously over a period of several hours, such as about 2, 4, 6, 8, 10, 12, 14 or 16 hours, or several days, such as 2, 3, 4, 5, 6, or 7 days, preferably from about 1 hour to about 24 hours and more preferably from about 3 hours to about 9 hours.
  • periodic doses can be administered in a single bolus or a small number of injections of the composition over a short period of time, typically less than 1 or 2 hours.
  • arginine butyrate has been administered over a period of 4 days with infusions for about 8 hours per day or overnight, followed by a period of 7 days of no treatment. This has been shown to be an effective regimen for many thalassemic disorders.
  • a substantial rise in HbF means that there are positive consequences that raise the patient's standard of living such as, for example, increased activity or mobility, fewer side- effects, fewer hospital stays or visits to the physician, or fewer transfusions.
  • HbF levels above 20% are generally considered to be sufficient to eliminate symptoms associated with sickle cell disease.
  • Pulsed administration can reduce the amount of a composition comprising an HbF-inducing agent thereof administered to the patient per dose, and/or per total treatment regimen with an increased effectiveness. Pulsed administration can provide a saving in time, effort and expense and a lower effective dose can lessen the number and severity of complications that can be experienced by a subject. As such, pulsing can be more effective than continuous administration of the same composition.
  • individual pulses can be delivered to a subject continuously over a period of several hours, such as about 2, 4, 6, 8, 10, 12, 14 or 16 hours, or several days, such as 2, 3, 4, 5, 6, or 7 days, or from about 1 hour to about 24 hours or from about 3 hours to about 9 hours.
  • periodic doses can be administered in a single bolus or a small number of injections of the composition comprising an HbF-inducing agent thereof over a short period of time, for example, less than 1 or 2 hours.
  • arginine butyrate can be administered over a period of 4 days with infusions for about 8 hours per day or overnight, followed by a period of 7 days of no treatment.
  • the interval between pulses or the interval of no delivery can be greater than 24 hours or can be greater than 48 hours, and can be for even longer such as for 3, 4, 5, 6, 7, 8, 9 or 10 days, two, three or four weeks or even longer.
  • the interval between pulses can be determined by one of ordinary skill in the art, for example, as demonstrated herein in the Examples, by measuring the gamma-globin expression level in the blood in the subject after administration of the pulse dose, and administering a pulse when the mRNA gamma-globin level reaches a certain predefined low threshold limit.
  • Such pre-defined low threshold limits can be determined by one of ordinary skill in the art, and can be, for example, about baseline level, or about 100% or about 200% above baseline level mRNA gamma-globin expression (e.g., mRNA gamma-globin expression without administration of an HbF-inducing agent).
  • the interval between pulses can be calculated by administering another dose of a composition comprising an HbF-inducing agent, and when the active component of the composition is no longer detectable in the patient prior to delivery of the next pulse.
  • intervals can also be calculated from the in vivo half-life of the composition.
  • the interval between pulses can also be determined by one of ordinary skill in the art, for example, as demonstrated herein in the Examples, by measuring the percent increase in absolute hemoglobin (see Fig 3), percent F-reticulocytes (see Figure 5), percent increase in F-cells (see Figure 6), in the blood in the subject after administration of the pulse dose, and administering a pulse when the mRNA gamma-globin or total hemoglobin (Hb) level increases by, for example about a 1.0 or about 0.5 g/dL increase in total hemoglobin or by 0.3-fold increase in fetal globin mRNA above levels prior to treatment.
  • Hb total hemoglobin
  • the number of pulses in a single therapeutic regimen can be as little as two, but can be from about 5 to 10, 10 to 20, 15 to 30 or more.
  • a subject can receive one or more compositions comprising an HbF-inducing agent for life according to the methods of this invention, for example, where the subject has a permanent or incurable blood disorder, e.g., an inherited blood disorder.
  • a permanent or incurable blood disorder e.g., an inherited blood disorder.
  • compositions can be administered by most any means, and can be delivered to the subject as an oral formulation, or injection (e.g. intravenous, subcutaneous, intra-arterial), infusion or instillation.
  • injection e.g. intravenous, subcutaneous, intra-arterial
  • infusion e.g. intravenous, subcutaneous, intra-arterial
  • instillation e.g. intrastillation.
  • Various methods and apparatus for pulsing compositions by infusion or other forms of delivery to the patient are disclosed in U.S. Pat. Nos. 4,747,825; 4,723,958; 4,948,592;
  • a composition comprising an HbF-inducing agent thereof can be administered to a subject for about 2, or about 3, or about 4, or about five days, or more than five days, and then a subsequently administered after an appropriate interval for an additional period of time, for example, for about 2, or about 3, or about 4, or about five days, or more than five days. Cycles of treatment may occur in immediate succession or with an interval of no treatment between cycles.
  • a composition comprising an HbF-inducing agent can be administered to a subject before a chemotherapeutic treatment, or radiation treatment is administered to the subject.
  • a composition comprising an HbF- inducing agent can be co-administered to a subject
  • a composition comprising an HbF-inducing agent can be co-administered with a pharmaceutical composition comprising an comprising one or more addition agents.
  • the pharmaceutical compositions can be provided by pulsed administration.
  • compositions comprising an HbF-inducing agent can be administered to a subject, followed by a chemotherapeutic treatment, or radiation treatment after an interval of time has passed, and this order of administration the same or similar time interval can be repeated, for example, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more times.
  • compositions for increasing the percentage of fetal hemoglobin in the blood of a subject comprising administering to a subject a composition comprising an HbF-inducing agent as disclosed herein as the free acid, a pharmaceutically acceptable salt, or ester thereof.
  • methods and compositions for increasing total hemoglobin in the blood of a subject comprising administering to the subject a composition comprising an HbF-inducing agent as disclosed herein as the free acid, a
  • compositions for increasing total hemoglobin, hematocrit, and red blood cells in a subject comprising administering to said subject an HbF-inducing agent as disclosed herein as the free acid, a pharmaceutically acceptable salt, or ester thereof. Further provided herein are methods and compositions for increasing total hemoglobin, hematocrit, or red blood cells, or a
  • administering an HbF-inducing agent as disclosed herein does not suppress erythropoiesis at concentrations associated with biologic activity.
  • administering an HbF-inducing agent as disclosed herein stimulates cell proliferation. In some embodiments, administering an HbF-inducing agent as disclosed herein inhibits apoptosis of erythroid progenitors. In further embodiments, administering an HbF- inducing agent as disclosed herein stimulates erythroid cell proliferation and survival. In some embodiments, administering an HbF-inducing agent as disclosed herein stimulates erythroid cell proliferation. In certain embodiments, administering an HbF-inducing agent as disclosed herein stimulates erythroid cell survival. In some embodiments, administering an HbF-inducing agent as disclosed herein stimulates red blood cell production.
  • administering an HbF-inducing agent as disclosed herein leads to a longer survival of sickled blood cells.
  • administering an HbF-inducing agent as disclosed herein stimulates erythropoiesis.
  • administering an HbF-inducing agent as disclosed herein induces expression of the fetal globin gene promoter.
  • administering an HbF-inducing agent as disclosed herein increases fetal globin levels.
  • administering an HbF-inducing agent as disclosed herein increases RBC production. In some instances, increased RBC production is assayed by reticulocytes, total hemoglobin (Hgb), and hematocrit (Hct).
  • administering an HbF-inducing agent as disclosed herein increases the amount of fetal globin in the blood of the subject. In some embodiments, administering an HbF-inducing agent as disclosed herein increases the amount of fetal hemoglobin in the blood of the subject. In certain embodiments, administering an HbF-inducing agent as disclosed herein increases the amount of total hemoglobin in the blood of the subject. In some embodiments, administering an HbF-inducing agent as disclosed herein increases the percentage of reticulocytes in the blood of the subject. In certain embodiments, administering an HbF-inducing agent as disclosed herein increases the number of reticulocytes in the blood of the subject. In some embodiments, administering an HbF-inducing agent as disclosed herein increases hematocrit.
  • an HbF-inducing agent as disclosed herein is effective at increasing percent HbF at a total daily dose which is below the maximum tolerated dose. In some instances, administering an HbF-inducing agent as disclosed herein does not necessitate the careful dose titration currently required for treatment with ST20.
  • an HbF-inducing agent as disclosed herein which is effective in increasing the percentage of HbF is significantly lower than the dose required for other SCFAD like arginine butyrate.
  • a subject can be administered an HbF-inducing agent as disclosed herein with other agents, including but not limited to 2,2- dimethylbutyrate is administered as sodium 2,2-dimethylbutyrate.
  • 2,2-Dimethylbutyrate includes, but is not limited to, 2,2-dimethylbutyric acid, sodium 2,2-dimethylbutyrate, potassium 2,2-dimethylbutyrate, magnesium 2,2-dimethylbutyrate, calcium 2,2-dimethylbutyrate, arginine 2,2-dimethylbutyrate, lysine 2,2-dimethylbutyrate, choline 2,2-dimethylbutyrate, methyl 2,2- dimethylbutyrate (2,2-dimethylbutyric acid methyl ester), ethyl 2,2- dimethylbutyrate, propyl 2,2-dimethylbutyrate, or isopropyl 2,2-dimethylbutyrate.
  • the subject has been diagnosed with a blood disorder.
  • the blood disorder is sickle cell disease. In other embodiments, the blood disorder is a beta thalassemia. In certain embodiments, the beta- thalassemia is beta thalassemia intermedia. In some embodiments, the beta thalassemia is beta- thalassemia major. In certain embodiments, the beta thalassemia is beta thalassemia minor (beta-thalassemia trait). In some embodiments, the beta thalassemia is HbE beta-thalassemia. In certain embodiments, the beta thalassemia is HbS beta-thalassemia.
  • a subject is administered a composition comprising an HbF- inducing agent as disclosed herein, daily.
  • administration is continuous.
  • the administration of a composition comprising an HbF-inducing agent as disclosed herein is by pulsed administration.
  • pulsed administration comprises administering an HbF-inducing agent pulse for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 9 months, about 12 months.
  • pulsed administration comprises intervals of not administering an HbF-inducing agent for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 9 months, about 12 months. In certain embodiments, administration is for the lifetime of the subject.
  • a composition comprising an HbF-inducing agent is administered every other day.
  • the pulsed administration comprises administering a composition comprising an HbF-inducing agent for about 5 days per week.
  • the pulsed administration comprises administering a composition comprising an HbF-inducing agent for about 5 days, followed by not administering an HbF-inducing agent for about 2 days. In certain embodiments, the pulsed administration comprises administering an HbF-inducing agent for about 2 weeks, followed by not administering an HbF- inducing agent for about 1 week. In some embodiments, the pulsed administration comprises administering an HbF-inducing agent for about 2 weeks, followed by not administering an HbF-inducing agent for about 2 weeks. In certain embodiments, the pulsed administration comprises administering an HbF-inducing agent for about 4 weeks, followed by not administering an HbF-inducing agent for about 1 week.
  • the pulsed administration comprises administering an HbF-inducing agent for about 4 weeks, followed by not administering an HbF-inducing agent for about 2 weeks. In further embodiments, the pulsed administration comprises administering an HbF-inducing agent for about 6 weeks, followed by not administering an HbF- inducing agent for about 2 weeks. In certain embodiments, the pulsed administration comprises administering an HbF-inducing agent for about 8 weeks, followed by not administering an HbF-inducing agent for about 2 weeks. In some embodiments, the pulsed administration comprises administering an HbF-inducing agent for about 8 weeks, followed by not administering an HbF-inducing agent for about 4 weeks.
  • administering a composition comprising an HbF-inducing agent to a subject with one genotype of beta thalassemia is more effective in raising percent HbF than administering DMB (ST20) to a subject with a different genotype of beta-thalassemia.
  • methods and compositions comprising diagnosing a beta-thalassemia genotype of a patient, determining a treatment plan considering the beta-thalassemia genotype, and optionally increasing the percentage of fetal hemoglobin in the blood of the patient, comprising administering to the patient an HbF-inducing agent as the free acid, a
  • a pharmaceutical composition comprising an HbF-inducing agent administered according to a method of the invention are administered orally in effective dosages, depending upon the weight, body surface area, and condition of the subject being treated. In some instances, variations occur depending upon the species of the subject being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out. In some embodiments, the administration of the pharmaceutical composition comprising an HbF-inducing agent administered according to a method of the invention are administered orally in effective dosages, depending upon the weight, body surface area, and condition of the subject being treated. In some instances, variations occur depending upon the species of the subject being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out. In some embodiments, the administration of the pharmaceutical composition comprising an
  • HbF-inducing agent according to a method of the invention is carried out in single or multiple doses.
  • the composition can be administered in a wide variety of different dosage forms, i.e., it may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, dragees, capsules, lozenges, troches, hard candies, aqueous suspensions, elixirs, syrups, and the like.
  • Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc.
  • oral pharmaceutical compositions can be suitably sweetened and/or flavored.
  • compositions comprising an HbF-inducing agent are suitable for oral administration.
  • compositions of the invention will typically comprise a compound of the present invention as the active ingredient and one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate.
  • solid dosage forms may also comprise: filters or extenders, such as starches, microcrystalline cellulose, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as
  • carboxymethylcellulose alginates, gelatin, polyvinylpyrrolidone, sucrose and/or acacia;
  • humectants such as glycerol
  • disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and/or sodium carbonate
  • solution retarding agents such as paraffin
  • absorption accelerators such as quaternary ammonium compounds
  • wetting agents such as cetyl alcohol and/or glycerol monostearate
  • absorbents such as kaolin and/or bentonite clay
  • lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and/or mixtures thereof
  • coloring agents such as glycerol
  • buffering agents such as glycerol
  • disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and/or sodium carbonate
  • solution retarding agents such as paraffin
  • absorption accelerators
  • compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
  • preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
  • the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
  • antioxidants can also be present in the pharmaceutical compositions of the invention.
  • pharmaceutically-acceptable antioxidants include: water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium
  • antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like
  • metal-chelating agents such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
  • Coating agents for tablets, capsules, pills and like include those used for enteric coatings, such as cellulose acetate phthalate (CAP), polyvinyl acetate phthalate (PVAP), hydroxypropyl methylcellulose phthalate, methacrylic acid, methacrylic acid ester copolymers, cellulose acetate trimellitate (CAT), carboxymethyl ethyl cellulose (CMEC), hydroxypropyl methyl cellulose acetate succinate (HPMCAS), and the like.
  • enteric coatings such as cellulose acetate phthalate (CAP), polyvinyl acetate phthalate (PVAP), hydroxypropyl methylcellulose phthalate, methacrylic acid, methacrylic acid ester copolymers, cellulose acetate trimellitate (CAT), carboxymethyl ethyl cellulose (CMEC), hydroxypropyl methyl cellulose acetate succinate (HPMCAS), and the like.
  • enteric coatings such as cellulose acetate phthal
  • compositions of the present invention may optionally contain opacifying agents and may be formulated so that they release the active ingredient only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
  • opacifying agents include polymeric substances and waxes.
  • the active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
  • compositions of the present invention may also be formulated to provide slow or controlled release of the active ingredient using, by way of example, hydroxypropyl methyl cellulose in varying proportions; or other polymer matrices, liposomes and/or microspheres.
  • Sustained release compositions can be formulated including those wherein the active component is derivatized with differentially degradable coatings, e.g., by
  • microencapsulation multiple coatings, etc.
  • composition, shape, and type of dosage forms of the invention will typically vary depending on their use. This aspect of the invention will be readily apparent to those skilled in the art. See, e.g., Remington's Pharmaceutical Sciences (1990) 18th ed., Mack Publishing, Eastern Pa.
  • the pharmaceutical compositions of the invention are packaged in a unit dosage form.
  • unit dosage form or “unit dose” refers to a physically discrete unit suitable for dosing a patient, i.e., each unit containing a predetermined quantity of active agent calculated to produce the desired therapeutic effect either alone or in combination with one or more additional units.
  • unit dosage forms may be capsules, tablets, pills, and the like.
  • Unit doses can also be prepared to contain any useful amount of an active ingredient (e.g., an HbF-inducing agent).
  • a unit dose can comprise 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg, 280 mg, 290 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 350 mg, 360 mg, 370 mg, 380 mg, 390 mg, 400 mg, 410 mg, 420 mg, 430 mg, 440 mg, 450 mg, 460 mg, 470 mg, 480 mg, 490 mg, 500 mg, 510 mg, 520 mg, 530 mg, 540 mg, 550 mg, 560 mg, 570 mg, 580 mg, 590 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg,
  • Administrations can be repeated on consecutive or non-consecutive days.
  • daily administrations can be performed for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, or more consecutive days.
  • administration of 10 mg/kg of an HbF-inducing agent is performed twice a day (at a total daily dose of 20 mg/kg) for 14 consecutive days.
  • administration may occur for multiple days, but on non- consecutive days separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more days.
  • administering 15 mg/kg of an HbF-inducing agent is performed on every other day following therapy onset. In another instance, administration of an HbF-inducing agent is performed for 5 days per week.
  • dosing regimens can be tailored to an individual patient, based on any number of clinically relevant parameters including, but not limited to toxicity, tolerance, side- effects, effectiveness, etc.
  • the pharmaceutical composition is administered alone or in combination with other known compositions for treating blood disorders in a subject, e.g., a mammal.
  • mammals include cats, dogs, pigs, horses, cows, rats, mice, monkeys, chimpanzees, baboons, and humans.
  • the mammal is a human.
  • the human is a child.
  • the human is under the age of 18.
  • the human is under the age of 10.
  • the human is under the age of 2.
  • the subject is suffering from a blood disorder.
  • the subject is at risk of suffering from a blood disorder.
  • compositions known in combination with are intended to include simultaneous administration of the composition of the invention and the known composition, administration of the composition of the invention first, followed by the known composition and administration of the known composition first, followed by the composition of the invention. Any of the compositions known in the art for treating blood disorders can be used in the methods of the invention.
  • an HbF-inducing agent for the treatment of blood disorders
  • concomitant administration of other pharmaceutical and nutraceutical compounds occurs.
  • persons suffering from sickle cell disease are given an HbF- inducing agent other agents as disclosed herein), folic acid supplements (for blood cell production), opioids or analgesics (for pain management), and/or antibiotics (for treating secondary infections).
  • administration of an HbF-inducing agent for the treatment of blood disorders is combined with the administration of natural or synthetic erythropoietin.
  • concomitant treatment with an HbF-inducing agent and a second agent occurs at the same time, or on different regimen schedules.
  • an HbF-inducing agent is an orally bio-available compound that is active at well tolerated doses.
  • compositions comprising HbF-inducing agents as described herein may be by oral, parenteral, sublingual, rectal, or enteral administration, or pulmonary absorption or topical application.
  • Compositions can be directly or indirectly administered to the patient. Indirect administration is performed, for example, by administering the composition to cells ex vivo and subsequently introducing the treated cells to the subject, e.g., human patient.
  • the cells may be obtained from the patient to be treated or from a genetically related or unrelated patient.
  • Related patients offer some advantage by lowering the compositions comprising HbF-inducing agents as described herein may be by oral, parenteral, sublingual, rectal, or enteral administration, or pulmonary absorption or topical application.
  • Compositions can be directly or indirectly administered to the patient. Indirect administration is performed, for example, by administering the composition to cells ex vivo and subsequently introducing the treated cells to the subject, e.g., human patient.
  • the cells may be obtained from the patient to be treated or
  • immunogenic response to the cells to be introduced For example, using techniques of antigen matching, immunologically compatible donors can be identified and utilized.
  • compositions comprising HbF-inducing agents can be purchased commercially and prepared as a mixed composition using techniques well-known to those of ordinary skill in the art.
  • Direct administration of a composition comprising HbF-inducing agents to a subject can be by oral, parenteral, sublingual, rectal such as suppository or enteral administration, or by pulmonary absorption or topical application.
  • Parenteral administration may be by intravenous (IV) injection, subcutaneous (s.c.) injection, intramuscular (i.m.) injection, intra- arterial injection, intrathecal (i.t.) injection, intra-peritoneal (i.p.) injection, or direct injection or other administration to the subject.
  • compositions comprising HbF-inducing agents and/or salts thereof can be added to the culture medium of cells ex vivo.
  • such compositions comprising HbF-inducing agents can contain pharmaceutically-acceptable carriers and other ingredients known to facilitate administration and/or enhance uptake (e.g., saline, dimethyl sulfoxide, lipid, polymer, affinity-based cell specific-targeting systems).
  • a composition comprising HbF-inducing agents and/or salts thereof can be incorporated in a gel, sponge, or other permeable matrix (e.g., formed as pellets or a disk) and placed in proximity to the endothelium for sustained, local release.
  • a composition comprising HbF-inducing agents and/or salts thereof can be administered in a single dose or in multiple doses which are administered at different times.
  • compositions comprising HbF-inducing agents and/or salts thereof can be administered by any known route.
  • a composition c comprising HbF- inducing agents and/or salts thereof can be administered by a mucosal, pulmonary, topical, or other localized or systemic route (e.g., enteral and parenteral).
  • parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intra-arterial, intrathecal, intraventricular, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, sub capsular, subarachnoid, intraspinal, intracerebro spinal, and intrasternal injection, infusion and other injection or infusion techniques, without limitation.
  • systemic administration "administered systemically", “peripheral administration” and
  • administered peripherally as used herein mean the administration of the agents as disclosed herein such that it enters the animal's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • phrases "pharmaceutically acceptable carrier” as used herein means a
  • composition or vehicle such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agents from one organ, or portion of the body, to another organ, or portion of the body.
  • a carrier must be "acceptable” in the sense of being compatible with the other ingredients of the formulation, for example the carrier does not decrease the impact of the agent on the treatment.
  • a carrier is pharmaceutically inert.
  • compositions comprising HbF-inducing agents and/or salts thereof can be made with the goals of achieving a favorable response in the subject with a blood disorder, e.g., thalassemia, aplastic anemia and hemoglobinopathy and avoiding undue toxicity or other harm thereto (i.e., safety). Therefore, "effective" refers to such choices that involve routine
  • a bolus of the formulation of a composition comprising HbF-inducing agents and/or salts thereof administered to an individual over a short time once a day is a convenient dosing schedule.
  • the effective daily dose can be divided into multiple doses for purposes of administration, for example, two to twelve doses per day.
  • Dosage levels of active ingredients in a pharmaceutical composition comprising HbF-inducing agents and/or salts thereof can also be varied so as to achieve a transient or sustained concentration of the compound or derivative thereof in an individual, especially in and around the blood circulation and to result in the desired therapeutic response or protection. But it is also within the skill of the art to start doses at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
  • the amount of a composition comprising HbF-inducing agents and/or salts thereof can be administered is dependent upon factors known to a person skilled in the art such as bioactivity and bioavailability of the compound (e.g., half-life in the body, stability, and metabolism); chemical properties of the compound (e.g., molecular weight, hydrophobicity, and solubility); route and scheduling of administration, and the like. It will also be understood that the specific dose level to be achieved for any particular individual can depend on a variety of factors, including age, gender, health, medical history, weight, combination with one or more other drugs, and severity of disease.
  • factors known to a person skilled in the art such as bioactivity and bioavailability of the compound (e.g., half-life in the body, stability, and metabolism); chemical properties of the compound (e.g., molecular weight, hydrophobicity, and solubility); route and scheduling of administration, and the like. It will also be understood that the specific dose level to be achieved for any particular individual can depend on
  • Dosages, formulations, dosage volumes, regimens, and methods for analyzing results aimed at increasing the proliferation of blood cells, and increasing absolute neutrophil count (ANC) can vary.
  • minimum and maximum effective dosages vary depending on the method of administration.
  • Increase in ANC in a subject can occur within a specific dosage range, which varies depending on, for example, the race, sex, gender, age, and overall health of the subject receiving the dosage, the route of administration, whether a composition comprising HbF- inducing agents and/or salts thereof is administered in conjunction with other molecules, and the specific regimen of administration of the composition comprising HbF-inducing agents and/or salts thereof.
  • nasal administration requires a smaller dosage than oral, enteral, rectal, or vaginal administration.
  • tablets can be formulated in accordance with conventional procedures employing solid carriers well-known in the art.
  • Capsules employed for oral formulations to be used with the methods of the present invention can be made from any pharmaceutically acceptable material, such as gelatin or cellulose derivatives.
  • Sustained release oral delivery systems and/or enteric coatings for orally administered dosage forms are also contemplated, such as those described in U.S. Pat. No. 4,704,295, "Enteric Film-Coating
  • compositions issued Jan. 5, 1982, which are all incorporated herein in their entirety by reference.
  • solid carriers include starch, sugar, bentonite, silica, and other commonly used carriers.
  • carriers and diluents which can be used in the formulations of the present invention include saline, syrup, dextrose, and water.
  • oral formulations of a composition comprising HbF-inducing agents and/or salts thereof can be in the form of a tablet formulation, for example, comprising HbF-inducing agents and/or salts thereof with an enteric polymer casing.
  • a tablet formulation for example, comprising HbF-inducing agents and/or salts thereof with an enteric polymer casing.
  • enteric polymer casing An example of such a preparation can be found in W02005/021002, which is incorporated herein in its entirety by reference.
  • the active material in the core can be present in a micronized or solubilized form.
  • the core can contain additives conventional to the art of compressed tablets.
  • Appropriate additives in such a tablet can comprise diluents such as anhydrous lactose, lactose monohydrate, calcium carbonate, magnesium carbonate, dicalcium phosphate or mixtures thereof; binders such as microcrystalline cellulose, hydroxypropylmethylcellulose,
  • a tablet comprises lactose as diluent.
  • a binder When a binder is present, it is preferably hydroxypropylmethyl cellulose.
  • a tablet comprises magnesium stearate as lubricant.
  • a tablet comprises croscarmellose sodium as disintegrant, or can comprise a microcrystalline cellulose.
  • a diluent can be present in a range of 10 - 80% by weight of the core.
  • the lubricant can be present in a range of 0.25- 2% by weight of the core.
  • disintegrant can be present in a range of 1 - 10% by weight of the core.
  • Microcrystalline cellulose if present, can be present in a range of 10- 80% by weight of the core.
  • the active ingredient e.g., HbF-inducing agents and/or a salt thereof comprises between 10 and 50% of the weight of the core, more preferably between 15 and 35% of the weight of the core (calculated as free base equivalent).
  • the core can contain any therapeutically suitable dosage level of the active ingredient e.g., HbF-inducing agents and/or a salts thereof, but preferably contains up to 150 mg as free base of the active ingredient. In some embodiments, the core contains 20, 30, 40, 50, 60, 80 or 100 mg as free base of the active ingredient.
  • the active ingredient e.g., HbF-inducing agents and/or a salts thereof can be present as the free base, or as any pharmaceutically acceptable salt.
  • the weight is adjusted such that the tablet contains the desired amount of active ingredient, calculated as free base of the salt.
  • the active ingredient e.g., HbF-inducing agents is present as a hydrochloride salt.
  • the core can be made from a compacted mixture of its
  • the components can be directly compressed, or can be granulated before compression.
  • Such granules can be formed by a conventional granulating process as known in the art.
  • the granules can be individually coated with an enteric casing, and then enclosed in a standard capsule casing.
  • the core can be surrounded by a casing which comprises an enteric polymer.
  • enteric polymers are cellulose acetate phthalate, cellulose acetate succinate, methylcellulose phthalate, ethylhydroxycellulose phthalate, polyvinylacetate pthalate, polyvinylbutyrate acetate, vinyl acetate-maleic anhydride copolymer, styrene-maleic mono-ester copolymer, methyl acrylate- methacrylic acid copolymer or methacrylate-methacrylic acid-octyl acrylate copolymer. These can be used either alone or in combination, or together with other polymers than those mentioned above.
  • the casing can also include insoluble substances which are neither decomposed nor solubilized in living bodies, such as alkyl cellulose derivatives such as ethyl cellulose, cross-linked polymers such as styrene-divinylbenzene copolymer,
  • polysaccharides having hydroxyl groups such as dextran, cellulose derivatives which are treated with bifunctional crosslinking agents such as epichlorohydrin, dichlorohydrin or 1, 2-, 3, 4- diepoxybutane.
  • the casing can also include starch and/or dextrin.
  • an enteric coating materials are the commercially available EUDRAGIT® enteric polymers such as EUDRAGIT® L, EUDRAGIT® Sand EUDRAGIT® NE, used alone or with a plasticizer. Such coatings are normally applied using a liquid medium, and the nature of the plasticizer depends upon whether the medium is aqueous or non-aqueous.
  • Plasticizers for use with aqueous medium include propylene glycol, triethyl citrate, acetyl triethyl citrate or CITROFLEX® or CITROFLEX® A2.
  • Non- aqueous plasticizers include these, and also diethyl and dibutyl phthalate and dibutyl sebacate.
  • a preferred plasticizer is Triethyl citrate. The quantity of plasticizer included will be apparent to those skilled in the art.
  • a casing can also include an anti-tack agent such as talc, silica or glyceryl monostearate.
  • an anti-tack agent is glyceryl monostearate.
  • the casing can include around 5 - 25 wt plasticizer and up to around 50 wt % of anti- tack agent, preferably 1-10 wt of anti-tack agent.
  • a surfactant can be included to aid with forming an aqueous suspension of the polymer.
  • Many examples of possible surfactants are known to the person skilled in the art.
  • surfactants are polysorbate 80, polysorbate 20, or sodium lauryl sulphate. If present, a surfactant can form 0.1- 10% of the casing, preferably 0.2- 5% and particularly preferably 0.5- 2%.
  • seal coat included between the core and the enteric coating.
  • a seal coat is a coating material which can be used to protect the enteric casing from possible chemical attack by any alkaline ingredients in the core.
  • the seal coat can also provide a smoother surface, thereby allowing easier attachment of the enteric casing.
  • a person skilled in the art would be aware of suitable coatings.
  • the seal coat is made of an OPADRY® coating, and particularly preferably it is OPADRY® White OY-S-28876.
  • the pharmaceutically active ingredient is HbF-inducing agents or a salt thereof.
  • an example of an enteric-coated formulation as described in W02005/021002 comprises varying amounts of HbF-inducing agents.
  • lactose monohydrate, microcrystalline cellulose, the active ingredient, the hydroxypropyl methyl cellulose and half of the croscarmellose sodium were screened into a 10 Litre Fielder high-shear blender (any suitable high shear blender could be used) and blended for 5 minutes at 300 rpm with the chopper off. The mixture was then granulated by the addition of about 750 ml water whilst continuing to blend.
  • the granules were dried in a Glatt 3/5 fluid bed drier, screened by Comil into a Pharmatec 5 Liter bin blender and then blended with any lactose anhydrous given in the formula plus the remainder of the croscarmellose sodium over 5 minutes at 20 rpm.
  • Magnesium stearate was screened into the blender and the mixing process continued for a further 1 minute at 10 rpm.
  • the lubricated mix was compressed using a Riva Piccolla rotary tablet press fitted with 9.5mm round normal convex punches (any suitable tablet press could be used).
  • the sealcoat, and subsequently the enteric coat are applied by spraying of an aqueous suspension of the coat ingredients in a Manesty 10 coater using parameters for the coating process as recommended by the manufacturers of the coating polymers (again, any suitable coater could be used).
  • Other enteric-coated preparations of this sort can be prepared by one skilled in the art, using these materials or their equivalents.
  • the compositions as disclosed herein is by an infusion pump (to infuse, for example, the compositions as disclosed herein into the subject's circulatory system) is generally used intravenously, although subcutaneous, arterial, and epidural infusions are occasionally used. Injectable forms of administration are sometimes preferred for maximal effect. When long-term administration by injection is necessary, medi-ports, in-dwelling catheters, or automatic pumping mechanisms are also preferred, wherein direct and immediate access is provided to the arteries in and around the heart and other major organs and organ systems.
  • compositions as disclosed herein comprising HbF-inducing agents and/or salts thereof can be administered to a specific site may be by transdermal transfusion, such as with a transdermal patch, by direct contact to the cells or tissue, if accessible, such as a skin tumor, or by administration to an internal site through an incision or some other artificial opening into the body.
  • compositions as disclosed herein comprising HbF-inducing agents and/or salts thereof can also be administered to the nasal passages as a spray. Diseases localized to the head and brain area are treatable in this fashion, as arteries of the nasal area provide a rapid and efficient access to the upper areas of the head.
  • Sprays also provide immediate access to the pulmonary system and are the preferable methods for administering compositions to these areas. Access to the gastrointestinal tract is gained using oral, enema, or injectable forms of administration.
  • administration of the compositions as disclosed herein comprising HbF-inducing agents and/or salts thereof to a subject is preferably oral. As a result, the subject can undergo administration of a composition comprising HbF- inducing agents and/or salts at home.
  • compositions comprising HbF-inducing agents and/or salts thereof are preferred for at least a portion of the cycle of therapy, as oral administration is usually the safest, most convenient, and economical mode of drug delivery. Consequently, compositions as disclosed herein comprising HbF-inducing agents and/or salts thereof can be modified to increase their oral bioavailable by reducing or eliminating their polarity. This can often be accomplished by formulating a composition with a complimentary reagent that neutralizes its polarity, or by modifying the compound with a neutralizing chemical group. Oral bioavailability is also a problem, because drugs are exposed to the extremes of gastric pH and gastric enzymes.
  • problems associated with oral bioavailability can be overcome by modifying the molecular structure to be able to withstand very low pH conditions and resist the enzymes of the gastric mucosa such as by neutralizing an ionic group, by covalently bonding an ionic interaction, or by stabilizing or removing a disulfide bond or other relatively labile bond.
  • compositions as disclosed herein comprising HbF-inducing agents and/or salts thereof can be used in combination with other agents to maximize the effect of the compositions administered in an additive or synergistic manner. Accordingly,
  • compositions as disclosed herein comprising HbF-inducing agents and/or salts thereof can also comprise proteinaceous agents such as growth factors and/or cytokines.
  • proteinaceous agents such as growth factors and/or cytokines.
  • Such proteinaceous agents may also be aminated, glycosylated, acylated, neutralized, phosphorylated, or otherwise derivatized to form compositions that are more suitable for the method of administration to the patient or for increased stability during shipping or storage.
  • Cytokines that are useful to be included in the compositions comprising HbF-inducing agents and/or salts thereof include, but are not limited to, granulocyte/macrophage colony stimulating factor (GM-CSF), stem cell factor (SCF erythropoietin (EPO), steel factor, activin, inhibin, the bone morphogenic proteins (BMPs), retinoic acid or retinoic acid derivatives such as retinol.
  • GM-CSF granulocyte/macrophage colony stimulating factor
  • SCF erythropoietin (EPO) stem cell factor
  • steel factor activin, inhibin
  • BMPs bone morphogenic proteins
  • retinoic acid or retinoic acid derivatives such as retinol.
  • compositions as disclosed herein comprising HbF-inducing agents and/or salts thereof can be physiologically stable at therapeutically effective concentrations.
  • Physiological stable compounds of HbF-inducing agents or salts thereof not break down or otherwise become ineffective upon administration to a subject or prior to having a desired effect.
  • Such reagents include amino acids such as arginine, glycine, alanine, asparagine, glutamine, histidine, or lysine, nucleic acids including nucleosides or nucleotides, or substituents such as carbohydrates, saccharides and polysaccharides, lipids, fatty acids, proteins, or protein fragments.
  • Useful coupling partners include, for example, glycol, such as polyethylene glycol, glucose, glycerol, glycerin, and other related substances.
  • Physiological stability of a composition comprising an HbF-inducing agent and/or salts thereof can be measured from a number of parameters such as the half-life of the an HbF- inducing agent compound or salts thereof, or the half-life of active metabolic products derived from the an HbF-inducing agent compound or salts thereof.
  • parameters such as the half-life of the an HbF- inducing agent compound or salts thereof, or the half-life of active metabolic products derived from the an HbF-inducing agent compound or salts thereof.
  • compositions comprising an HbF-inducing agent and/or salts thereof have in vivo half-lives of greater than about fifteen minutes, greater than about one hour, greater than about two hours, and greater than about four hours, eight hours, twelve hours, or longer.
  • a compound of an HbF- inducing agent or its salts is stable using this criteria, however, physiological stability can also be measured by observing the duration of biological effects on the patient.
  • Clinical symptoms that are important from the patient's perspective include a reduced frequency or duration, or elimination of the need for transfusions or chelation therapy.
  • a stable composition comprising an HbF-inducing agent and/or salts thereof has an in vivo half-life of greater than about 15 minutes, a serum half-life of greater than about 15 minutes, or a biological effect which continues for greater than 15 minutes after treatment has been terminated or the serum level of the compound has decreased by more than half.
  • compositions as disclosed herein comprising an HbF-inducing agent and/or salts thereof are also not significantly biotransformed, degraded, or excreted by catabolic processes associated with metabolism. Although there may be some biotransformation, degradation, or excretion, these functions are not significant, if the composition is able to exert its desired effect.
  • compositions as disclosed herein comprising an HbF-inducing agent and/or salts thereof are also safe at effective dosages.
  • Safe compositions are compositions that are not substantially toxic (e.g. cytotoxic or myelotoxic), or mutagenic at required dosages, do not cause adverse reactions or side effects, and are well-tolerated. Although side effects may occur, compositions are substantially safe if the benefits achieved from their use outweigh disadvantages that may be attributable to side effects. Unwanted side effects include nausea, vomiting, hepatic or renal damage or failure, hypersensitivity, allergic reactions, cardiovascular problems, gastrointestinal disturbances, seizures, and other central nervous system difficulties, fever, bleeding or hemorrhaging, serum abnormalities, and respiratory difficulties.
  • compositions useful for treating blood disorders preferably do not substantially affect the viability of a blood cell such as a normal mammalian blood cell.
  • Normal cell viability or the viability of blood cell, e.g., hematopoietic cell can be determined from analyzing the effects of the composition on one or more biological processes of the blood or hematopoietic cell.
  • Useful combination therapies will be understood and appreciated by those of skill in the art. Potential advantages of such combination therapies include the ability to use less of each of the individual active ingredients to minimize toxic side effects, synergistic improvements in efficacy, improved ease of administration or use, and/or reduced overall expense of compound preparation or formulation.
  • the composition comprising an HbF-inducing agent and/or salts thereof can be administered to an adult, an adolescent, a child, a neonate, an infant or in utero. In some embodiments, a composition comprising an HbF-inducing agent and/or salts thereof can be administered to a subject via a continuous infusion throughout the cycle of therapy.
  • compositions comprising an HbF-inducing agent and/or salts thereof can be administered to a the subject over a single span of a few to several hours per day every day throughout the first period of the cycle of therapy.
  • a composition comprising an HbF-inducing agent and/or salts thereof can be administered to a subject in a single parenteral bolus, or orally, daily for several days throughout the treatment regimen or cycle, or weekly.
  • a composition comprising an HbF-inducing agent and/or salts thereof can be prepared in solution as a dispersion, mixture, liquid, spray, capsule, or as a dry solid such as a powder or pill, as appropriate or desired.
  • Solid forms may be processed into tablets or capsules or mixed or dissolved with a liquid such as water, alcohol, saline or other salt solutions, glycerol, saccharides or polysaccharide, oil, or a relatively inert solid or liquid.
  • compositions comprising an HbF- inducing agent and/or salts thereof can further comprise agents to increase shelf-life, such as preservatives, anti- oxidants, and other components necessary and suitable for manufacture and distribution of the composition.
  • compositions comprising an HbF-inducing agent and/or salts thereof can further comprise a pharmaceutically acceptable carrier or excipient.
  • Carriers are chemical or multi-chemical compounds that do not significantly alter or affect the active ingredients of the compositions.
  • Carriers may be single substances or chemical or physical combinations of these substances.
  • a composition comprising an HbF-inducing agent and/or salts thereof can contain chemicals that are substantially non-toxic.
  • substantially non-toxic means that the composition, although possibly possessing some degree of toxicity, is not harmful to the long-term health of the patient.
  • the active component of the composition may not be toxic at the required levels, there may also be problems associated with administering the necessary volume or amount of the final form of the composition to the patient.
  • composition comprising an HbF-inducing agent contains a salt, although the active ingredient may be at a concentration that is safe and effective, there can be a harmful build-up of sodium, potassium, or another ion. With a reduced requirement for the composition or at least the active component of that composition, the likelihood of such problems can be reduced or even eliminated. Consequently, although patients may suffer minor or short term detrimental side- effects, the advantages of taking the composition outweigh the negative consequences.
  • the amount of an HbF-inducing agent that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound that produces a therapeutic effect. Generally out of one hundred percent, this amount will range from about
  • the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 (the dose therapeutically effective in 50% of the population) with little or no toxicity.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
  • the therapeutically effective dose of an HbF-inducing agent can be estimated initially from cell culture assays, for example, one can measure the percent increase in mRNA gamma- globin in the blood on administration, as disclosed herein.
  • a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the therapeutic which achieves a half-maximal inhibition of symptoms) as determined in cell culture.
  • IC50 i.e., the concentration of the therapeutic which achieves a half-maximal inhibition of symptoms
  • the dosage of an HbF-inducing agent may be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment.
  • the compositions are
  • an HbF-inducing agent or a prodrug thereof is given at a dose from 1 ⁇ g/kg to 150 mg/kg, 1 ⁇ g /kg to 100 mg/kg, 1 ⁇ g /kg to 50 mg/kg, 1 ⁇ g /kg to 20 mg/kg, 1 ⁇ g /kg to 10 mg/kg, 1 ⁇ g /kg to 1 mg/kg, 100 ⁇ g /kg to 100 mg/kg, 100 ⁇ g /kg to 50 mg/kg, 100 ⁇ g /kg to 20 mg/kg, 100 ⁇ g /kg to 10 mg/kg, 100 ⁇ g/kg to 1 mg/kg, 1 mg/kg to 100 mg/kg, 1 mg/kg to 50 mg/kg, 1 mg/kg to 20 mg/kg, 1 mg/kg to 10 mg/kg, 10 mg/kg to 100 mg/kg, 10 mg/kg to 50 mg/kg, or 10 mg/kg to 20 mg/kg.
  • ranges given here include all intermediate ranges, for example, the range 1 mg/kg to 10 mg/kg includes 1 mg/kg to 2 mg/kg, 1 mg/kg to 3 mg/kg, 1 mg/kg to 4 mg/kg, 1 mg/kg to 5 mg/kg, 1 mg/kg to 6 mg/kg, 1 mg/kg to 7 mg/kg, 1 mg/kg to 8 mg/kg, 1 mg/kg to 9 mg/kg, 2 mg/kg to 10 mg/kg, 3 mg/kg to 10 mg/kg, 4 mg/kg to 10 mg/kg, 5 mg/kg to 10 mg/kg, 6 mg/kg to 10 mg/kg, 7 mg/kg to 10 mg/kg, 8 mg/kg to 10 mg/kg, 9 mg/kg to 10 mg/kg, and the like.
  • ranges intermediate to the given above are also within the scope of this invention, for example, in the range 1 mg/kg to 10 mg/kg, dose ranges such as 2 mg/kg to 8 mg/kg, 3 mg/kg to 7 mg/kg, 4 mg/kg to 6 mg/kg, and the like.
  • compositions comprising an HbF-inducing agent are administered at a dosage so that an HbF-inducing agent or a metabolite thereof has an in vivo, e.g., serum or blood, concentration of less than 500 nM, less than 400 nM, less than 300 nM, less than 250 nM, less than 200 nM, less than 150 nM, less than 100 nM, less than 50 nM, less than 25 nM, less than 20, nM, less than 10 nM, less than 5 nM, less than 1 nM, less than 0.5 nM, less than 0.1 nM, less than 0.05 nM, less than 0.01 nM, less than 0.005 nM, or less than 0.001 nM after 15 mins, 30 mins, 1 hr, 1.5 hrs, 2 hrs, 2.5 hrs, 3 hrs, 4 hrs, 5 hrs, 6 hrs, 7 hrs, 8 hrs, 9
  • the dosing schedule can vary from once a week to daily depending on a number of clinical factors, such as the subject's sensitivity to an HbF-inducing agent acid.
  • the desired dose can be administered every day or every third, fourth, fifth, or sixth day.
  • the desired dose can be administered at one time or divided into subdoses, e.g., 2-4 subdoses and administered over a period of time, e.g., at appropriate intervals through the day or other appropriate schedule.
  • Such sub-doses can be administered as unit dosage forms.
  • administration is chronic, e.g., one or more doses daily over a period of weeks or months.
  • dosing schedules are administration daily, twice daily, three times daily or four or more times daily over a period of 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months or more.
  • HbF-inducing agent or a prodrug thereof can be administrated to a subject in combination with one or more pharmaceutically active agents.
  • exemplary pharmaceutically active compound include, but are not limited to, those found in Harrison's Principles of Internal Medicine, 13th Edition, Eds. T.R. Harrison et al.
  • a counter-screening assay to determine the gamma-globin-specificity of hits using an assay which measures gamma-globin gene promoter induction relative to beta-globin gene promoter induction.
  • This assay is fluorescence-based, and consists of a dual-luciferase reporter construct containing the LCR and beta-globin promoter linked to renilla luciferase and the A- gamma-globin promoter linked to firefly luciferase ⁇ LCR-beta-pr-Rluc-Agamma-pr-Fluc cassette), stably-transfected into GM979 cells.
  • the orientation of the promoters and ⁇ 3 ⁇ 4 allowed detection only of strong, specific inducers of the gamma-globin gene promoter.
  • Human erythroid progenitors were cultured from peripheral blood samples, exposed to the test compounds at varying concentrations and for varying durations and analyzed for globin chain mRNA ratios.
  • Erythroid progenitors were cultured from cord blood CD34+ cells. Briefly, CD34+ cells in the human cord blood were separated using a Ficoll-paque density gradient. CD34+ cells were cultured in H4230 medium containing 2mM L-glutamine, 1% Methylcellulose in Iscove's Medium, 30% Fetal Bovine Serum, 1% Bovine Serum Albumin and 10-4 M beta- mercaptoethanol.
  • Methylcellulose H4230 medium was supplemented with EPO (0.5 U/ml) and IL-3 (20 ng/ml) to support BFU-e growth.
  • Cells were cultured in 35 x 100mm mini-dishes and incubated in a humidified atmosphere containing 5% C02, at 37°C. Different concentrations of the test compounds were added at the time the cultures were established. Each compound was tested in three different cultures. BFU-e colonies grown in mini-dishes were counted on day 14 and harvested for mRNA analysis.
  • MS-275 was administered intravenously at a dose of 10 mg/kg once daily, 4-5 days per week for four weeks, to assess gamma-globin gene expression in baboon 5002. Levels of gamma-globin mRNA expression and globin chain synthesis were assessed in baboons before and during treatment with test compounds. A washout period between administrations of different compounds in the same baboon was provided. MS-275 and desloratidine both induced fetal globin mRNA and total hemoglobin levels increased following MS-275 administration.
  • Benserazide is identified as a novel HbF inducing agent using a High throughput Screening Assay (HTS).
  • HTS High throughput Screening Assay
  • Benserazide was discovered in a novel high-throughput screening (HTS) program which interrogated 3 chemical libraries of compounds and included a library of medicinal products which are already approved in USA or in the European Union (by the European Medicines Agency) for other medical indications.
  • HTS High throughput Screening Assay
  • the potential of Benserazide to induce HbF was unknown.
  • a gamma-globin gene promoter linked to GFP Figure 1
  • the HTS assay was adapted from low throughput to a robotic high-throughput screening system, and screening was performed over a 3-log concentration range, on the diverse chemical libraries.
  • the screening assay was developed from a cell-based reporter, stably transfected with a construct containing the 1.4-kilobase (kb) Kpnl-Bglll fragment of the human locus control region (LCR) linked to the gamma-globin gene promoter and the enhanced green fluorescent protein (EGFP) reporter gene (Figure IB).
  • kb 1.4-kilobase
  • LCR human locus control region
  • EGFP enhanced green fluorescent protein reporter gene
  • the HTS assay was developed in 96-well format on a Tecan SpectraFluor Plus, incorporating multiple positive and negative control wells in each plate. Optimal fluorescence measurements were identified. Analysis of two sets of 10,000 compounds was performed, testing over a 3-log range of concentrations. From the library of compounds and US and EMA approved medicinal products tested, a small panel of approved therapeutics were found to induce ⁇ -globin expression (Figure IB).
  • the activity of the potential candidate compounds identified using the HTS was validated in a secondary assay using dual lucif erases linked to the fetal and adult globin promoters. The secondary assay confirmed that Benserazide induces only the gamma globin promoter and not general globin promoters. The racemate form of Benserazide was selected for further analysis and was referred to as PB-04.
  • EXAMPLE 2 Benserazide induces a mean 42-fold induction of Fetal globin (gamma-globin) mRNA in erythroid progenitors from sickle cell and beta thalassemia patients.
  • Erythroid progenitors were isolated from cord blood and from human patients with beta thalassaemia or sickle cell disease and CD34+ cells were enriched.
  • CD34+ erythroid progenitors were cultured for a first phase to eliminate white cells and then in a second phase to expand and differentiate the erythroid cells in the presence of erythropoietin. This method produces 95% erythroid cells.
  • Benserazide caused a mean 42-fold increase in fetal globin (gamma-globin) mRNA in human erythroid progenitors ( Figure 2), which is significantly higher than the magnitude of induction by other known fetal globin inducing agents, which only caused a 2-6.5 fold increase in gamma-globin mRNA.
  • EXAMPLE 3 In vivo results: Anemic Baboon Study. Benserazide and Desloratidine (DLT) induce a 33-fold and 11-fold increase in fetal Globin Induction respectively, and increase erythroid cell production in anemic baboons. The effect of Benserazide to induce fetal globin was assessed in vivo in a baboon model of anemia. This baboon model (Pace et al., 2002) requires that anemia be present for induction of gamma-globin to be detected.
  • DLT Desloratidine
  • One juvenile baboon (Papio hamadryas anubis) was chronically phlebotomized (by 3.7 to 5 mL/kg/day) to achieve and maintain stable anemia with total hemoglobin of 7.0 to 7.5 g/dl, a level necessary for the modulation of globin genes in this species.
  • the animals were supplemented with iron dextran and folic acid to support active erythropoiesis.
  • the phlebotomy regimen effectively exchanged the animals' total blood volume every 10 to 20 days.
  • Assays of gamma-globin mRNA expression were performed with the approval of the corresponding animal research institutions.
  • the drug candidate was administered based on doses adjusted for more rapid metabolism in the baboon, but projected as equivalent to doses previously used or studied in humans as follows:
  • Benserazide was administered orally, at 1 mg/kg for 4 days/week and 2 mg/kg for two weeks. A washout period was provided between administrations of different compounds in the same baboon. Levels of gamma-globin mRNA expression, total hemoglobin, and % F-cells were assessed before and during treatment with test compounds. Benserazide was compared to 2 other candidates (i) desloratadine (DLT), which was administered orally (0.5 mg/kg/dose), three times a week over two weeks, and (ii) MS-275, which was administered orally three times a week for two weeks at 0.2 mg/kg/dose.
  • DLT desloratadine
  • MS-275 which was administered orally three times a week for two weeks at 0.2 mg/kg/dose.
  • Benserazide Doses of Benserazide are shown in the bars above the graph, with Benserazide administered at 1 mg/kg (Open squares) and 2 mg/kg (dark squares). The time course is consistent with the time required for new red blood cells to develop and enter the circulation. A lag follows each time -off the drug.
  • Gamma globin mRNA was analyzed by RT-PCR prior to drug administration, 3 times/week during and following drug administration, and change from baseline was assessed. Changes in gamma-globin mRNA is shown in Figure 3A. Benserazide resulted in up to 33-fold induction of gamma-globin mRNA in vivo.
  • Benserazide also caused an increase in total hemoglobin (Hb) (by 1.5g/dL) ( Figure 3B) despite the daily phlebotomy, indicating that Benserazide has an independent effect on erythropoiesis, which is also beneficial in the treatment of patients with beta- thalassemia and sickle cell disease.
  • Benserazide BEN
  • Desloratidine DLT
  • EXAMPLE 4 In vivo results: Anemic Baboon Study. Benserazide results in a 15% increase the number of F-reticulocytes in Anemic Baboons. F-reticulocytes of Benserazide treated anemic baboons were analyzed using flow cytometry. The peripheral blood of the baboons was analyzed using Flow cytometry to detect HbF protein and proportions of cells expressing fetal globin protein as previously described (Pace, 2002). Briefly, cells were washed with PBS containing 0.1% BSA, and fixed. After washing twice, the cells were permeabilized in PBS with 0.1% Triton-X100 and incubated.
  • Figure 5 shows that Benserazide increases F-reticulocytes by 15% following the 2 mg/kg dose. The time course of response is consistent with the time required for new red blood cells to mature and enter the circulation.
  • EXAMPLE 5 In vivo results: Transgenic Murine Study. Benserazide induces human ⁇ -globin gene expression in a mouse model. The effect of Benserazide was compared to a known Hb inducer (Hydoxyurea (HU) in a transgenic mice model comprising the entire human non-alpha (gamma delta beta-globin) gene locus. Mice transgenic for the human beta-globin gene locus including the locus control region (LCR) were previously described (Pace 2002).
  • Hb inducer Hydoxyurea (HU)
  • LCR locus control region
  • mice were treated with either (i) hydroxyurea (HU) - administered at 100 mg/kg/dose once daily for 5 days/week, or (ii) Benserazide - administered at 2 mg/kg/dose, 3 times per week for 5 weeks or (iii) water in the same volume (100 microliters) as the drug candidates as a negative control. Dosing was performed by intraperitoneal injection (i.p) to ensure consistent drug delivery. Blood was sampled for globin mRNA and for F-cell quantitation and fluorescent intensity of F-cells by flow cytometry.
  • Hb Total hemoglobin
  • Benserazide induced an absolute 13% mean increase in the number of F-cells (from 0.1% to 9% (mice #1), 0.4% to 18% (mice #2), and 0.13% to 12% (mice #3); and 10 to 33-fold increase in mean fluorescence intensity (MFI) (Figure 6B). Responses were observed within one week, and continually increased in the Benserazide treated mice, whereas the percentage of F-cells declined in the Hydroxyurea-treated mice.
  • Figure 9 depicts a comparison of the magnitude of fetal globin mRNA induction over baseline levels in anemic baboons by new drugs compared to hydroxyurea (HU) ( Figure 9A), and proportions of new red blood cells with fetal globin protein, F-reticulocytes, (Figure 9B).
  • Reponses are significantly higher than those induced by the only US and EM A- approved drug, hydroxyurea.
  • F-reticulocytes are 3 to 5 times higher with the new drugs than induced by hydroxyurea.
  • Figures 10A-F depict Benserazide reduction of binding of two repressors, LSD1 and HDAC3, to the fetal globin gene promoter in erythroid progenitors from sources as indicated.
  • Figure 11 depicts the suppression of repressor proteins BCL11A and KLF1 in different erythroid progenitors treated with new drugs as compared with untreated control levels by Western blot analysis.
  • arginine butyrate is rapidly-metabolized, requires intravenous (IV) infusions which are difficult long-term, and is also a broad HDAC inhibitor, suppressing cell proliferation.
  • IV intravenous
  • RB7 is particularly novel, in that it displaces a repressor complex containing HDAC3 and recruits EKLF to the promoter. Yet all such new chemical entities must pass daunting, lengthy, and costly toxicology and manufacturing hurdles, and may have unknown safety issues.
  • the system utilizes a stably-transfected construct containing the human LCR linked to the gamma-globin gene promoter and the enhanced green fluorescent protein (EGFP) reporter gene, and was adapted from low-throughput to high-throughput application.
  • the HTS assay also allowed an estimate of the cytotoxicity of the tested compounds. Because EGFP mRNA has long stability, positive changes average 1.2- to 2-fold; weak inducers are not detectable in this system; and 2-fold or higher induction indicates very strong inducers of beta-globin promoter activity. Two campaigns screening 10,000 compounds were performed. From the "FDA-approved compound” library, a number of hits were identified, of which a few showed higher potency than butyrates in secondary, confirmatory assays.
  • confirmatory assays included a dual-luciferase reporter assay that analyzes specificity by comparative induction of the gamma- vs beta-globin promoters, globin mRNA analyses by RT- PCR, and initial erythroid cultures from normal subjects with low baseline HbF Bfu-e; these published assays are validated for their correlation with subsequent clinical activity in humans, with induction in Bfu-e having greater correlation than reporter assays.
  • the HTS assay identified 10 drugs, already FDA-approved by the U.S. or Canadian drug authorities for other indications (and confirmed in secondary assays) as potent inducers of gamma-globin gene expression (active at 2-3 logs lower concentration than butyrate, and generating higher induction of gamma-globin mRNA in human erythroid progenitors). These drugs hits are 3-8 times more potent than an oral SCFAD HbF inducer currently in clinical trials (SDMB). Three drugs were selected with high potency in specifically inducing the gamma- globin promoter. One (MS-275) also suppresses a repressor of gamma-globin transcription, BCL-11A. Two of the 3 are approved in young children, which is important as organ damage in these diseases begins in childhood.
  • the targeted therapeutic action is induction of high-level expression of fetal globin, without concomitant erythroid cell cytostasis or cytotoxicity.
  • Two clinically-approved therapeutics (desloratidine and benserazide) and a third extensively clinically- studied
  • MS-275 were selected for evaluation in patients' erythroid progenitors.
  • the agents have shown 5-fold gamma-globin induction in erythroid cells cultured from normal subjects, compared to untreated controls from the same subjects, and each had greater effects than induced by HU or butyrate. Because hemoglobinopathy patients (as opposed to cultures from normal subjects) have a wide range of basal HbF levels which may affect the magnitude of responses to therapeutics. These agents augment HbF expression to the greatest degree in erythroid progenitors cultured from patients with lower baseline HbF levels.
  • the 3 preferred oral therapeutics include:
  • Desloratidine A drug requiring prescription for treatment of allergic symptoms, with a benign safety profile in extended use. In baboon studies, this agent induced HbF within 4 days of administration to a higher degree than almost all other test agents within the same animal..
  • Benserazide (BEN) Approved in a combination formulation to enhance the PK profile of L-dopa, and reported to have no clinical effects itself. No adverse effects of this therapeutic or drug interactions have been identified. A proprietary extended-release formulation is developed. This drug has never been approved for any use except in combination with other drugs.
  • MS-275 an oral, class I-specific HDAC inhibitor. Its primary adverse effect is fatigue, but it is administered infrequently, once every 2 weeks, and is therefore worthwhile to evaluate. It does not have adverse cardiac side effects of many pan-HDAC inhibitors.
  • MS-275 suppresses expression of BCL-11A, a transcriptional repressor which down-regulates beta-globin
  • MS-275 would be given in an intermittent or pulsed regimen in patients.
  • BEN is a preferred pharmaceutical agent as it has slight pro- erythropoietic activity.
  • DLT is another preferred agent as stable GMP formulations for extended release are available.
  • Erythroid progenitors are cultured +/- the 3 candidate drugs and vehicle controls, and +/- HU, at the optimal concentrations established. Two drugs which have shown activity in clinical trials (Arginine butyrate and hydroxyurea) are used as positive controls for comparison with the candidate drugs.
  • the gamma-globin induction assays are performed on erythroid progenitors cultured from 3 groups of at least 15 genotyped sickle cell patients, stratified for baseline HbF in 3 ranges: low (less than 2%), average HbF (3-8%), and the typical range in HU -responsive adults (8-11 ). HbF levels are obtained on the submitted de-identified samples by HPLC. Approximately 8 samples with baseline HbF levels greater than 15% may also be analyzed. Analyses is performed as previously described on cultured progenitors
  • Paired-tests and Fisher's exact test are used to determine if significant differences are produced in% F-cells, HbF, and gamma-globin mRNA parameters, compared to levels in the same subjects' vehicle-treated control cultures. Whether addition of HU with test drugs results in higher induction compared to cultures treated with HU alone, or with test drugs alone, are statistically evaluated; t-tests and Wilcoxon tests for paired differences and other tests as indicated are used. Positive changes in greater than 35% of cultures are based on positive changes in 75% of progenitors cultured from normal subjects; however, the magnitude of change in
  • hemoglobinopathy patients' progenitors is much more likely significant. All drug candidates should increase HbF expression in greater than or equal to 60% of subjects' colonies, based on response rates in cells cultured from normal subjects. As growth of erythroid cells is inhibited by HU, and by HDAC inhibitors to a lesser degree, HU (positive control) are utilized at low nanomolar concentrations. If colony growth is severely suppressed by HU, it may be added transiently. Selection is based on the agent that produces the greatest magnitude of HbF induction compared to untreated controls in cultures from the low and moderate baseline HbF levels.
  • selection of the clinical candidate are based on effects on erythroid proliferation and side-effect profile (favoring DLT or Benserazide), and the most rapid regulatory path (DLT).
  • Formulation of the drug Desloratidine may include higher dose requirements than required for allergy treatment.
  • Benserazide may include extended-release preparations based on its published pharmacokinetics. Benserazide is currently formulated commercially in
  • Desloratidine is prepared in a proprietary medicinal formulation as a solution or tablet.
  • Validated assays for the analytical work are established for the required formulation development for all 3.
  • Formulation developments include pH solubility and pH stability profiles; selection of buffer and buffer strength; selection of formulation type- solution, tablet, immediate or extended release; selection of co-solvents and complexing agents, (e.g., for extended release, Benserazide); selection of preservatives based on pH; selection of sweeteners and flavoring agents (from a panel of 15 taste-masking agents); composition of final formulation (active pharmaceutical ingredient [API], excipients, preservatives); dissolution of any extended release formulation; establishment of specifications for future batches, including sterility testing; accelerated stability study.
  • API active pharmaceutical ingredient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de manière générale des compositions contenant des composés chimiques et des compositions et des formulations pharmaceutiques des composés qui augmentent l'hémoglobine totale ou la protéine globine, telle que la globine embryonnaire ou fœtale, ou la prolifération de cellules exprimant l'hémoglobine. Des composés préférés comprennent le bensérazide, un inhibiteur de l'histone désacétylase à base de benzamide, tel que l'entinostat ou un ou plusieurs parmi l'ambroxol, la desloratadine, le resvératrol ou le NSC-95397. Ces compositions peuvent être utilisées pour traiter ou prévenir les symptômes associés à des drépanocytoses, des thalassémies bêta et d'autres déficiences des cellules sanguines et troubles sanguins. L'invention concerne également des procédés d'administration de ces compositions à des sujets et d'utilisation comme aide médicale pour le traitement et la prévention d'anémies provoquées par des mutations du gène de la globine et d'autres troubles de des globules rouges.
PCT/US2014/051887 2013-08-20 2014-08-20 Inducteurs chimiques d'hémoglobine foetale WO2015026939A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2922013A CA2922013C (fr) 2013-08-20 2014-08-20 Inducteurs chimiques d'hemoglobine foetale

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361867965P 2013-08-20 2013-08-20
US61/867,965 2013-08-20

Publications (1)

Publication Number Publication Date
WO2015026939A1 true WO2015026939A1 (fr) 2015-02-26

Family

ID=52484128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/051887 WO2015026939A1 (fr) 2013-08-20 2014-08-20 Inducteurs chimiques d'hémoglobine foetale

Country Status (2)

Country Link
CA (2) CA2922013C (fr)
WO (1) WO2015026939A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137567A1 (en) * 2006-05-09 2009-05-28 Hemaquest Pharmaceuticals, Inc. Methods for Treating Blood Disorders
US20110015168A1 (en) * 2007-01-19 2011-01-20 Mitchell Keegan Methods for increasing levels of human fetal hemoglobin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137567A1 (en) * 2006-05-09 2009-05-28 Hemaquest Pharmaceuticals, Inc. Methods for Treating Blood Disorders
US20110015168A1 (en) * 2007-01-19 2011-01-20 Mitchell Keegan Methods for increasing levels of human fetal hemoglobin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PERRINE ET AL.: "Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies", HEMATOL ONCOL CLIN NORTH AM., vol. 28, no. 2, 1 April 2014 (2014-04-01), pages 233 - 248 *
SANGERMAN ET AL.: "Identification of New and Diverse Inducers of Fetal Hemoglobin with High Throughput Screening (HTS", AMER. SOC. HEMATOLOGY, 56TH ANNUAL MEETING AND EXPOSITION, 6 December 2010 (2010-12-06), SAN FRANCISCO, CA *

Also Published As

Publication number Publication date
CA3120111A1 (fr) 2015-02-26
CA2922013C (fr) 2021-06-08
CA2922013A1 (fr) 2015-02-26

Similar Documents

Publication Publication Date Title
ES2959111T3 (es) Composiciones farmaceuticas que comprenden glitazonas y activadores de Nrf2
US9675595B2 (en) Synergistic combinations of PI3K- and MEK-inhibitors
WO2012031125A2 (fr) Inversion des effets d'une anesthésie générale par administration de phénidate de méthyle, d'amphétamine, de modafinil, d'amantadine, et/ou de caféine
WO2012142413A2 (fr) Compositions à base de nitrite et leurs utilisations
AU2021200321A1 (en) ADO-Resistant Cysteamine Analogs And Uses Thereof
EP3386967A1 (fr) Combinaisons pour le traitement de calculs rénaux
CA3159368A1 (fr) Methodes therapeutiques a l'aide de vadadustat
US20150125526A1 (en) Use of Cysteamine and Derivatives Thereof to Treat Mitochondrial Diseases
WO2013086002A1 (fr) Compositions, procédé de préparation de ladite composition et méthode de traitement du cancer
US9018176B2 (en) Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders
US10111846B2 (en) S isomers of alpha-methyl-hydrocinnamic acid for the treatment of blood disorders
CA2922013C (fr) Inducteurs chimiques d'hemoglobine foetale
CA3218585A1 (fr) Composition pour le traitement d'etats pathologiques auto-immuns, allo-immuns, inflammatoires et mitochondriaux, et leurs utilisations
WO2007037258A1 (fr) Agent thérapeutique destiné au trouble déficitaire de l’attention avec hyperactivité
KR101436644B1 (ko) 당뇨병 치료제
RU2538666C2 (ru) Препарат для нормализации процессов перекисного окисления липидов у животных
JP2017109987A (ja) ＥｒｂＢ４＋炎症性マクロファージによって媒介される疾患の治療方法
US8685952B2 (en) Method for the treatment of diabetes
US20210145783A1 (en) Compositions and Methods for Treating Sickle Cell Disease
KR20180033957A (ko) 칼콘 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 미토콘드리아의 산소 소모율 감소에 의해 야기되는 질환의 예방 또는 치료용 약학 조성물
EP3441070A1 (fr) Médicament pour prévenir ou traiter l'acidose lactique
WO2024026509A2 (fr) Sélection de thérapie et traitement de troubles neurodégénératifs
JP2016533323A (ja) 多発性硬化症の治療のためのラキニモド併用療法
AU2014346703A1 (en) Use of cysteamine and derivatives thereof to treat mitochondrial diseases
WO2005117853A1 (fr) Agent thérapeutique pour l'hyperlipémie et agent thérapeutique pour le diabète

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14838553

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2922013

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14838553

Country of ref document: EP

Kind code of ref document: A1